Merck sales and marketing update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Zepatier grazoprevir/elbasvir from Merck to treat HCV genotypes 1a, 1b and 4 infection in adults. NICE said the incremental cost-effectiveness ratio (ICER) for all genotypes compared with other treatments was below L20,000 ($26,692) per quality-adjusted life year (QALY) gained. ...